Needham & Company Maintains a 'Hold' on Cubist Pharmaceuticals (CBST); 4Q11 Review. U.S. Cubicin Sales Guidance for 2012 In-line with Our Expectations

Needham & Company maintains a 'Hold' on Cubist Pharmaceuticals (NASDAQ: CBST).

Needham analyst says, "Cubist reviewed corporate goals for 2012 and provided financial guidance for the year in a quarterly conference call yesterday. Management guided for $770-795M in 2012 U.S. Cubicin sales, bracketing our expectations coming into the call, but somewhat under the $794M consensus figure. Cubist continues to execute commercially with Cubicin and we expect this to continue in 2012. Nevertheless, we maintain our rating, awaiting clarity on CXA-201 development in HAPB/VABP, a challenging indication. Other than trial initiations, we expect minimal pipeline news flow this year. We expect the stock to perform in-line with the market."

For an analyst ratings summary and ratings history on Cubist Pharmaceuticals click here. For more ratings news on Cubist Pharmaceuticals click here.

Shares of Cubist Pharmaceuticals closed at $40.40 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Coherent (COHR) PT Raised to $420 at Needham
• Needham Reiterates Buy Rating on WhiteFiber Inc (WYFI)
• Veritone (VERI) PT Lowered to $5 at Needham